Nivolumab + Everolimus
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Conditions
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Trial Timeline
Oct 9, 2012 → Jul 19, 2021
NCT ID
NCT01668784About Nivolumab + Everolimus
Nivolumab + Everolimus is a phase 3 stage product being developed by Ono Pharmaceutical for Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01668784. Target conditions include Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01668784 | Phase 3 | Completed |
Competing Products
20 competing products in Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma